desonide (Desonide) ointment
[Perrigo New York]
For Dermatological Use Only - Not for Ophthalmic Use Rx Only
Desonide Ointment contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-, (11β,16 α)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents.
Chemically, desonide, the active ingredient in Desonide Ointment, is C24H32O6. It has the following structural formula:
Desonide has the molecular weight of 416.51. It is a white to off-white powder. The solubility of desonide in distilled water saturated with ether is 184 mg/L.
Each gram of Desonide Ointment contains 0.5 milligrams of desonide microdispersed in a base of white petrolatum.
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity, of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Studies performed with Desonide Ointment indicate that it is in the low range of potency as compared with other topical corticosteroids.
Desonide Ointment is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
It should not be used for longer than two weeks unless directed by a physician.
Desonide Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.
Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression.
This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppressions.
No specific studies relevant to potential HPA suppression have been conducted with Desonide Ointment.
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.
Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS -Pediatric use)
If irritation develops, Desonide Ointment should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.
If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Desonide Ointment should be discontinued until the infection has been adequately controlled.
Desonide Ointment should not be used in the presence of infection at the treatment site, hypersensitivity to corticosteroids, or pre-existing skin atrophy.
Desonide Ointment should not be used in the eyes.
FOR EXTERNAL USE ONLY.
Patients using topical corticosteroids should receive the following information and instructions:
The following test may be helpful in evaluating patients for HPA axis suppression:
Long-term animal studies have not been performed to evaluate the carcinogenic, mutagenic, or fertility impairment potential of Desonide Ointment.
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with Desonide Ointment. It is also not known whether Desonide Ointment can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. There are no adequate and well-controlled studies in pregnant women. Desonide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Desonide Ointment is administered to a nursing woman.
Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment.
Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children.
HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
In controlled clinical trials, the total incidence of adverse reactions associated with the use of Desonide Ointment was approximately 6 %. These were erythema, induration, pruritus, irritation, oiliness, and peripheral edema.
The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation.
Topically applied Desonide Ointment can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
Desonide Ointment should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition.
As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Desonide Ointment should not be used with occlusive dressings.
Desonide Ointment, 0.05% is supplied in 15 and 60 gram tubes.
Store between 15° and 30° C (59° and 86° F).
DISTRIBUTED BY PERRIGO, ALLEGAN, MI 49010
I423-N R 1005